Mixed linear and non-linear disposition of lazabemide, a reversible and selective inhibitor of monoamine oxidase B. 1994

T W Guentert, and N H Holford, and J P Pfefen, and J Dingemanse
Department of Clinical Pharmacology, F. Hoffmann-La Roche Ltd, Basel, Switzerland.

1. Single oral doses (100-300 mg) and multiple oral doses (100-350 mg 12 hourly for 7 days) of lazabemide were administered to 35 young and 40 elderly healthy subjects. Plasma concentrations of unchanged drug were determined to study the dose-concentration relationship. 2. The elimination phase time course of lazabemide concentrations indicated concentration-dependent elimination after both single and multiple dosing. Nevertheless, maximum concentrations and areas under concentration-time curves increased almost proportionally with dose and accumulation after chronic dosing was less than a factor of 2; steady-state concentrations were achieved by the third day of dosing. The apparent half-life determining accumulation was approximately 8-9 h. 3. Drug absorption commenced rapidly after a dose; two components to the absorption process were detectable in young subjects possibly due to simultaneous administration of multiple tablets at the higher doses. 4. Observations after single and multiple dosing were described with a compartmental model allowing for parallel saturable (population mean +/- s.d.: maximum elimination rate Vmax/F: 2.8 +/- 1.4 mg h-1; concentration at half-maximum elimination Km: 36 +/- 19 micrograms l-1) and first-order (CL/F 16 +/- 3.8 l h-1) elimination pathways. No important difference between the young and the elderly subjects was noted in absorption or disposition parameters of lazabemide.

UI MeSH Term Description Entries
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D008996 Monoamine Oxidase Inhibitors A chemically heterogeneous group of drugs that have in common the ability to block oxidative deamination of naturally occurring monoamines. (From Gilman, et al., Goodman and Gilman's The Pharmacological Basis of Therapeutics, 8th ed, p414) MAO Inhibitor,MAO Inhibitors,Reversible Inhibitors of Monoamine Oxidase,Monoamine Oxidase Inhibitor,RIMA (Reversible Inhibitor of Monoamine Oxidase A),Reversible Inhibitor of Monoamine Oxidase,Inhibitor, MAO,Inhibitor, Monoamine Oxidase,Inhibitors, MAO,Inhibitors, Monoamine Oxidase
D010848 Picolinic Acids Compounds with general formula C5H4N(CO2H) derived from PYRIDINE, having a carboxylic acid substituent at the 2-position. Acids, Picolinic
D012016 Reference Values The range or frequency distribution of a measurement in a population (of organisms, organs or things) that has not been selected for the presence of disease or abnormality. Normal Range,Normal Values,Reference Ranges,Normal Ranges,Normal Value,Range, Normal,Range, Reference,Ranges, Normal,Ranges, Reference,Reference Range,Reference Value,Value, Normal,Value, Reference,Values, Normal,Values, Reference
D004305 Dose-Response Relationship, Drug The relationship between the dose of an administered drug and the response of the organism to the drug. Dose Response Relationship, Drug,Dose-Response Relationships, Drug,Drug Dose-Response Relationship,Drug Dose-Response Relationships,Relationship, Drug Dose-Response,Relationships, Drug Dose-Response
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults
D000368 Aged A person 65 years of age or older. For a person older than 79 years, AGED, 80 AND OVER is available. Elderly

Related Publications

T W Guentert, and N H Holford, and J P Pfefen, and J Dingemanse
October 2002, Addiction (Abingdon, England),
T W Guentert, and N H Holford, and J P Pfefen, and J Dingemanse
September 2000, Biochemical pharmacology,
T W Guentert, and N H Holford, and J P Pfefen, and J Dingemanse
June 2010, Acta crystallographica. Section C, Crystal structure communications,
T W Guentert, and N H Holford, and J P Pfefen, and J Dingemanse
January 2017, BMC complementary and alternative medicine,
T W Guentert, and N H Holford, and J P Pfefen, and J Dingemanse
August 1993, Journal of clinical psychopharmacology,
T W Guentert, and N H Holford, and J P Pfefen, and J Dingemanse
January 1978, Biochemical pharmacology,
T W Guentert, and N H Holford, and J P Pfefen, and J Dingemanse
July 1996, The Journal of pharmacology and experimental therapeutics,
T W Guentert, and N H Holford, and J P Pfefen, and J Dingemanse
January 2016, Central nervous system agents in medicinal chemistry,
T W Guentert, and N H Holford, and J P Pfefen, and J Dingemanse
May 1994, Japanese journal of pharmacology,
T W Guentert, and N H Holford, and J P Pfefen, and J Dingemanse
April 1996, The Journal of pharmacology and experimental therapeutics,
Copied contents to your clipboard!